PAX1 Methylation Hallmarks Promising Accuracy for Cervical Cancer Screening in Asians: Results from a Meta-Analysis

Kong, Ling-Ying; Du, Wei; Wang, Li; Yang, Zhi; Zhang, Hongsheng

doi:10.7754/clin.lab.2015.150232

Cited by 6 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mersakova et al (2018) and Rong et al (2019) have recently shown that CADM1 is a potential biomarker for cervical cancer. There was a significant difference in the promoter Kan et al, 2014;Lai et al, 2014;Kong et al, 2015;Nikolaidis et al, 2015;Xu et al, 2015Xu et al, , 2018Chen et al, 2016;Liou et al, 2016;Huang et al, 2017;Fang et al, Lee et al, 2006;Yeon et al, 2018 methylation of plasma CADM1 and its D-dimer between healthy individuals and those with cervical cancer. Combining these factors to predict metastasis revealed high specificity (90.5%) and sensitivity (80.4%) (Rong et al, 2019).…”

Section: Dna Methylation In the Early Diagnosis Of Cervical Cancermentioning

confidence: 97%

“…Using the methylation status of PAX1 to determine the cancerous nature (and CIN1-3) of samples from Shanghai, China is associated with a sensitivity and specificity of 81 and 93%, respectively; however, the sensitivity and specificity for cancer versus CIN2/3 is 32% and 90%, respectively (Xu et al, 2015). Single mutations in PAX1 have been accurate in diagnosing cervical/HSIL in a group of 15 individuals with a specificity and sensitivity of 89% and 80%, respectively (Kong et al, 2015). Lai et al (2014) have demonstrated that methylated PAX1 can be used for detecting CIN3 + lesions with a sensitivity and specificity of 64% and 91%, respectively in Taiwanese patients.…”

Section: Diagnostic Dna Methylation Biomarkers For Hpv-positive and Nmentioning

confidence: 99%

See 1 more Smart Citation

DNA Methylation and Hydroxymethylation in Cervical Cancer: Diagnosis, Prognosis and Treatment

Zhu

Tian

et al. 2020

Front. Genet.

View full text Add to dashboard Cite

Recent discoveries have led to the development of novel ideas and techniques that have helped elucidate the correlation between epigenetics and tumor biology. Nowadays, the field of tumor genetics has evolved to include a new type of regulation by epigenetics. An increasing number of studies have demonstrated the importance of DNA methylation and hydroxymethylation in specific genes in the progression of cervical cancer. Determining the methylation and hydroxymethylation profiles of these genes will help in the early prevention and diagnosis, monitoring recurrence, prognosis, and treatment of patients with cervical cancer. In this review, we focus on the significance of aberrant DNA methylation and hydroxymethylation in cervical cancer and the use of these epigenetic signatures in clinical settings.

show abstract

Section: Dna Methylation In the Early Diagnosis Of Cervical Cancermentioning

confidence: 97%

Section: Diagnostic Dna Methylation Biomarkers For Hpv-positive and Nmentioning

confidence: 99%

DNA Methylation and Hydroxymethylation in Cervical Cancer: Diagnosis, Prognosis and Treatment

Zhu

Tian

et al. 2020

Front. Genet.

View full text Add to dashboard Cite

show abstract

“…One meta‐analysis reviewed 1,385 subjects with various stages of CIN and normal cervical pathology, finding that the sensitivity and specificity of PAX1 methylation in CIN3+ vs. normal samples were 0.77 and 0.92, respectively (Nikolaidis et al, ). Additionally, 15 individual studies showed that single PAX1 methylation allowed the accurate differential diagnosis of cervical cancer/HSIL patients from normal individuals with a sensitivity of 0.80 and a specificity of 0.89 (Kong et al, ).…”

Section: Pax1 Methylation and Cervical Cancermentioning

confidence: 99%

“…Methylation of PAX1 promoter is an important epigenetic regulation associating to the development and the metastasis of the tumor. PAX1 gene in cervical and ovarian cancer is silenced by methylation and is considered as a tumor suppressor gene Hassan, Hafez, Kamel, & Zekri, 2017;Kan et al, 2014;Kong, Du, Wang, Yang, & Zhang, 2015;Su et al, 2009). 2 | PAX1 METHYLATION AND CERVICAL CANCER…”

mentioning

confidence: 99%

The promising role of PAX1 (aliases: HUP48, OFC2) gene methylation in cancer screening

Fang

Wang

Liou

et al. 2019

Molec Gen & Gen Med

View full text Add to dashboard Cite

Background Paired‐box gene 1 ( PAX1 ), a member of the PAX family, plays a role in pattern formation during embryogenesis, and might be essential for development of the vertebral column. Methods PAX1 is silenced by methylation in several cancers and is considered a tumor suppressor gene. Our previous studies reported PAX1 as hypermethylated in cervical cancer tissues, thereby suggesting it as a potential screening marker. Recently, an increasing number of studies have confirmed PAX1 methylation as a promising biomarker in cervical cancer based on its excellent discriminatory ability between high‐grade cervical lesions and normal tissues, resulting in a reduced necessity for referral for colposcopy and biopsy. Additionally, PAX1 is also hypermethylated in other tumors, including those associated with epithelial ovarian cancer, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, and endometrial carcinoma, and shows relatively good sensitivity and specificity for the detection of these tumors. Results This review summarizes reports of PAX1 methylation and its promising role in cancer screening, especially that associated with cervical cancer. Conclusion According to current evidence, combined testing for human papillomavirus and PAX1 methylation analysis represents an efficacious cervical cancer‐screening protocol.

show abstract

“…Combining the triage by MAL/miR-124-2 methylation analysis with threshold-80 and HPV16/18 genotyping can reach higher CIN3 + sensitivity and identify women at the highest risk of cervical (pre)cancer [ 72 , 73 ]. Combining parallel testing of PAX1, DAPK1, RARB, WIF1, and SLIT2 DNA methylation and HPV DNA increases specificity to identify cervical cancer and achieves better precision than single HPV DNA testing does [ 74 – 76 ]. Above all, methylation of some genes has a prospect to be an auxiliary biomarker for cervical cancer screening.…”

Section: Dna Methylation In Cervical Cancer and Cinmentioning

confidence: 99%

The Progress of Methylation Regulation in Gene Expression of Cervical Cancer

Feng

Dong

Chang

et al. 2018

International Journal of Genomics

View full text Add to dashboard Cite

Cervical cancer is one of the most common gynecological tumors in females, which is closely related to high-rate HPV infection. Methylation alteration is a type of epigenetic decoration that regulates the expression of genes without changing the DNA sequence, and it is essential for the progression of cervical cancer in pathogenesis while reflecting the prognosis and therapeutic sensitivity in clinical practice. Hydroxymethylation has been discovered in recent years, thus making 5-hmC, the more stable marker, attract more attention in the field of methylation research. As markers of methylation, 5-hmC and 5-mC together with 5-foC and 5-caC draw the outline of the reversible cycle, and 6-mA takes part in the methylation of RNA, especially mRNA. Furthermore, methylation modification participates in ncRNA regulation and histone decoration. In this review, we focus on recent advances in the understanding of methylation regulation in the process of cervical cancer, as well as HPV and CIN, to identify the significant impact on the prospect of overcoming cervical cancer.

show abstract

PAX1 Methylation Hallmarks Promising Accuracy for Cervical Cancer Screening in Asians: Results from a Meta-Analysis

Cited by 6 publications

References 0 publications

DNA Methylation and Hydroxymethylation in Cervical Cancer: Diagnosis, Prognosis and Treatment

DNA Methylation and Hydroxymethylation in Cervical Cancer: Diagnosis, Prognosis and Treatment

The promising role of PAX1 (aliases: HUP48, OFC2) gene methylation in cancer screening

The Progress of Methylation Regulation in Gene Expression of Cervical Cancer

Contact Info

Product

Resources

About